Clinical review of glimepiride

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 4, 2001, Pages 699-713

  McCall, A L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Insulin secretagogue; Sulfonylureus; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROPAMIDE; CIMETIDINE; COUMARIN; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ISOPHANE INSULIN; METFORMIN; MICONAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POTASSIUM CHANNEL; PROBENECID; PROPRANOLOL; RAMIPRIL; RANITIDINE; SULFONYLUREA; SULFONYLUREA RECEPTOR; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD TOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; HEADACHE; HEART DISEASE; HEART MUSCLE ISCHEMIA; HEPATIC PORPHYRIA; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN RELEASE; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; RECEPTOR AFFINITY; SKIN ALLERGY; VERTIGO; DRUG INTERACTION; REVIEW;

CLINICAL TRIALS; DIABETES MELLITUS, NON-INSULIN-DEPENDENT; DRUG INTERACTIONS; HUMAN; HYPOGLYCEMIC AGENTS; SULFONYLUREA COMPOUNDS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0035012433     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.4.699     Document Type: Article

References (52)

1. The 'thrifty' hypotheses: Clinical and epidemiological significance for non-insulin-dependent diabetes mellitus and cardiovascular disease risk factors
2. Diabetes Trends in the U.S.: 1990-1998
3. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010
4. Metabolic and adipose risk factors for NIDDM and coronary disease in third-generation Japanese-American men and women with impaired glucose tolerance
5. Banting lecture 1988. Role of insulin resistance in human disease
6. The fetal and childhood growth of persons who develop type 2 diabetes
7. Non-insulin-dependent diabetes mellitus: A genetically programmed failure of the beta cell to compensate for insulin resistance
8. The glucose receptor. A defective mechanism in diabetes mellitus distinct from the beta adrenergic receptor
9. Overview of 6 years' therapy of Type II diabetes: A progressive disease
10. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
11. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results
12. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34)
13. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
14. Nonhypoglycemic Effects of thiazolidinediones
15. ATP-sensitive K+ channels and insulin secretion: Their role in health and disease
16. Glimepiride: Role of a new sulfonylurea in the treatment of type 2 diabetes mellitus
17. 3H]glimepiride
18. Glucose toxicity
19. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP)
20. The Achilles heel of the University Group Diabetes Program
21. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction
22. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Stu
23. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide
24. Comparison of the efficacy of glibenclamide and glimepiride in reperfusion-induced arrhythmias in rats
25. Individual sulfonylureas and serious hypoglycemia in older people
26. Rates of hypoglycemia in users of sulfonylureas
27. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men
28. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas
29. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment
30. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients
31. Metabolites of hypoglycemic sulfonylureas in kidney failure. Experience with glibenclamide
32. Glibenclamide-associated hypoglycaemia: A report on 57 cases
33. Oral hypoglycemic agents
34. Drug-induced hypoglycemia
35. The use of sulphonylureas in the elderly
36. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus
37. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients
38. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful
39. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents
40. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials
41. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study
42. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): A double-blind comparison with glibenclamide
43. Glimepiride. A review of its use in the management of type 2 diabetes mellitus
44. Evening insulin strategy
45. Combined insulin and sulfonylurea therapy for type 2 diabetes mellitus
46. Combined therapy with a sulfonylurea plus evening insulin: Safe, reliable, and becoming routine
47. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials
48. Comparison of bedtime insulin regimens in patients with Type 2 diabetes mellitus: A randomized, controlled trial
49. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone
50. An overview of the safety and tolerance of glimepiride